Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

BACKGROUND: Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen presentation, generate new tumor-specific T cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hägerbrand, Karin, Varas, Laura, Deronic, Adnan, Nyesiga, Barnabas, Sundstedt, Anette, Ljung, Lill, Sakellariou, Christina, Werchau, Doreen, Thagesson, Mia, Gomez Jimenez, David, Greiff, Lennart, Celander, Mona, Smedenfors, Kristine, Rosén, Anna, Bölükbas, Deniz, Carlsson, Fredrika, Levin, Mattias, Säll, Anna, von Schantz, Laura, Lindstedt, Malin, Ellmark, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660648/
https://www.ncbi.nlm.nih.gov/pubmed/36323431
http://dx.doi.org/10.1136/jitc-2022-005018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660648/
https://www.ncbi.nlm.nih.gov/pubmed/36323431
http://dx.doi.org/10.1136/jitc-2022-005018

Ejemplares similares